Statins for high-risk patients without heart disease or high cholesterol

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1225, 2006, Pages 1-3

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROPHYLAXIS; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; ARTICLE; BLOOD; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG INTERACTION; HYPERTENSION;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PRAVASTATIN; PYRROLES; SIMVASTATIN;

EID: 33644834533     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (10)

1. KK Ray and CP Cannon. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46:1425.
2. C Baigent et al; Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.
3. PS Sever et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavia Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.
4. PS Sever et al; ASCOT Investigators. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005; 28:1151.
5. HM Colhoun et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.
7. R Colllins et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361:2005.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA 2002; 288:2998.
9. Safety of aggressive statin therapy. Med Lett Drugs Ther 2004; 46:93.
10. Cost based on most recent data (October 31, 2005) from retail pharmacies nationwide available from NDCHealth, a healthcare information services company.